What is InformedDNA?
InformedDNA stands as the definitive authority on the appropriate use of genetic testing, leveraging a robust team of board-certified genetics specialists. The company's core mission is to ensure that patients, clinicians, health plans, health systems, employers, and pharmaceutical companies have access to high-quality genetic services. InformedDNA's key offerings encompass clinical genetic counseling, genetic testing utilization management, genetic testing payment integrity, and expert genetics support for clinical trials, positioning it as a critical partner in navigating the complexities of genomic medicine.
How much funding has InformedDNA raised?
InformedDNA has raised a total of $22.2M across 4 funding rounds:
Private Equity
$7.7M
Unspecified
$3M
Private Equity
$5M
Private Equity
$6.5M
Private Equity (2013): $7.7M, investors not publicly disclosed
Unspecified (2013): $3M led by MPM Capital
Private Equity (2014): $5M supported by Zaffre Investments, LLC.
Private Equity (2016): $6.5M, investors not publicly disclosed
Key Investors in InformedDNA
Zaffre Investments, LLC.
Zaffre Investments, LLC, a subsidiary of Blue Cross Blue Shield of Massachusetts, focuses on healthcare investments aimed at improving healthcare delivery. They are stage-agnostic and seek to partner with companies across the healthcare landscape, including health information technology and consumer solutions.
MPM Capital
MPM Capital is a venture capital firm specializing in early-stage investments in the life sciences sector. They focus on converting scientific breakthroughs into therapeutics and have a strong track record in the biotechnology and pharmaceutical industries.
What's next for InformedDNA?
With substantial enterprise-level backing, InformedDNA is poised for accelerated growth and expanded service offerings. The company's focus on genetic testing utilization management and payment integrity is particularly relevant in an era of increasing genomic data and its integration into clinical practice. Future strategic initiatives are likely to involve further development of its expert network, enhancement of its technology platforms for managing genetic testing, and deeper partnerships with health plans and health systems to optimize patient care pathways and control costs associated with genetic diagnostics. This investment signals a strong market confidence in InformedDNA's model and its capacity to shape the future of genetic testing.
See full InformedDNA company page
